Skip to main content

Exocrine pancreatic cancer: Symptoms at presentation and their relation to tumour site and stage

Abstract

Introduction. The need to detect pancreatic cancer at earlier stages is undisputed. We recorded the signs and symptoms of patients presenting with exocrine pancreatic cancer and evaluated their association with clinical characteristics such as tumour site and disease stage.

Patients and methods. All patients (n=185) with exocrine pancreatic cancer newly diagnosed at five general hospitals in Eastern Spain were prospectively recruited over 3 years. Symptoms were elicited through personal interviews and signs were recorded by the attending physician on admission.

Results. At diagnosis, one third of tumours of the pancreas head were in stage I and another third in stage IV. None of the tumours of the body and tail were in stage I, and over 80% were in stage IV (p<0.001). At presentation, the most frequent symptoms were asthenia (86%), anorexia (83%), weight-loss (85%), abdominal pain (79%), and choluria (59%). Cholestatic symptoms were more common in tumours affecting only the pancreatic head (p<0.001). There was a clear trend towards more localized tumours with increasing numbers of cholestatic signs (p<0.001). Asthenia, anorexia and weight-loss were unrelated to stage. An increased symptom-to-diagnosis interval was associated with more advanced stage (p=0.048).

Conclusions. Proper attention to signs and symptoms, especially cholestasis, may help identify patients with pancreatic cancer at an earlier stage. Results also provide a current picture of the semiology of pancreatic cancer which could be of use in studies on the potential of proteomic tests in the early detection of this neoplasm.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Porta M, Malats N, Jariod M, et al. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. Lancet. 1999;354:2125–9.

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–57.

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Weiderpass E, Partanen T, Kaaks R, et al. Pancreatic cancer: Occurrence, trends, and environmental etiology. A review. Scand J Work Environ Health. 1999;24:165–74.

    Google Scholar 

  4. 4.

    Ekbom A, Hunter D. Pancreatic cancer. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of Cancer Epidemiology. New York: Oxford University Press; 2002. p. 233–47.

    Google Scholar 

  5. 5.

    Anderson KE, Potter JD, Mack TM. Pancreatic cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer Epidemiology and Prevention. New York: Oxford University Press; 1996. p. 725–71.

    Google Scholar 

  6. 6.

    Lowenfels AB, Maisonneuve P. Pancreatic cancer: development of a unifying etiologic concept. In: Löhr JM, Colcher D, Hallingswirth MA, Liebe S. Cell and molecular biology of pancreatic carcinoma. Recent developments in research and experimental therapy. Ann New York Acad Sci. 1999;880:191–200.

    Article  CAS  Google Scholar 

  7. 7.

    Hart AR. Pancreatic cancer: any prospects for prevention? Postgrad Med J. 1999;75:521–6.

    PubMed  CAS  Article  Google Scholar 

  8. 8.

    Trede M, Carter DC. Clinical evaluation and preoperative assessment. In: Trede M, Carter DC, editors. Surgery of the pancreas. New York: Churchill Livingstone; 1997. p. 459–70.

    Google Scholar 

  9. 9.

    Fearon KCH, Wigmore SJ, Carter DC. Chemotherapy and radiotherapy in the treatment of pancreatic cancer. In: Trede M, Carter DC, editors. Surgery of the pancreas. New York: Churchill Livingstone; 1997. p. 551–62.

    Google Scholar 

  10. 10.

    DiMagno EP, Reber HA, Tempero MA (American Gastroenterological Association Clinical Practice and Practice Economics Committee). American Gastroenterological Association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 1999;117:1463–84.

    Article  Google Scholar 

  11. 11.

    Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996;78 Suppl 3:627–32.

    Google Scholar 

  12. 12.

    Levin B. An overview of preventive strategies for pancreatic cancer. Ann Oncol. 1999;10 Suppl 4:S193–6.

    Article  Google Scholar 

  13. 13.

    Anonymous. Early diagnosis and screening for pancreatic cancer [editorial]. Lancet. 1986;2:783–4.

  14. 14.

    DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol. 1999;10 Supl 4:140–2.

    PubMed  Article  Google Scholar 

  15. 15.

    Gullo L, Tomassetti P, Migliori M, Casadei R, Marrano D. Do early symptoms of pancreatic cancer exist that can allow an earlier diagnosis? Pancreas. 2001;22:210–3.

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Beger HG, Warshaw AL, Büchler MW, et al, editors. The pancreas. Oxford: Blackwell; 1998.

    Google Scholar 

  17. 17.

    Howard JM, Idezuki Y, Ihse I, Prinz RA, editors. Surgical diseases of the pancreas. 3rd. ed. Baltimore: Williams and Wilkins; 1998.

    Google Scholar 

  18. 18.

    Neoptolemos J, Lemoine NR, editors. Pancreatic cancer. Molecular and clinical advances. Oxford: Blackwell; 1996.

    Google Scholar 

  19. 19.

    Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, editors. The pancreas. Biology, pathobiology, and disease. 2nd. ed. New York: Raven; 1993.

    Google Scholar 

  20. 20.

    Falk J, Keidan R, Rigo PK, Dmuchowski C. Adenocarcinoma of the pancreatic head: a community teaching hospital’s experience from 1982 to 1992. Am Surg. 1999;65:15–8.

    PubMed  CAS  Google Scholar 

  21. 21.

    Faivre J, Forman D, Estève J, Obradovic M, San M and the EUROCARE Working Group. Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. Eur J Cancer. 1998;34:2184–90.

    Article  CAS  Google Scholar 

  22. 22.

    Gudjonsson B. Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg. 1995;181:483–503.

    PubMed  CAS  Google Scholar 

  23. 23.

    Gordon TA, Burleyson GP, Tielsch JM, Cameron JL. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg. 1995;221:43–9.

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Real FX. A “catastrophic hypothesis” for pancreas cancer progression. Gastroenterology. 2003;124:1958–64.

    PubMed  Article  Google Scholar 

  25. 25.

    Maguire A, Porta M, Malats N, Gallén M, Piñol JL, Fernández E. Cancer survival and the duration of symptoms. An analysis of possible forms of the risk function. Eur J Cancer. 1994;30A:785–92.

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Richter JM. Clinical assessment of pancreatic cancer. In: Beger HG, Warshaw AL, Büchler MW, et al, editors. The pancreas. Vol. 2. Oxford: Blackwell; 1998. p. 950–2.

    Google Scholar 

  27. 27.

    Modolell I, Guarner L, Malagelada JR. Vagaries of clinical presentation of pancreatic and biliary tract cancer. Ann Oncol. 1999;10 Supl 4:82–4.

    PubMed  Article  Google Scholar 

  28. 28.

    Lankisch PG. Clinical evaluation. En: Beger HG, Warshaw AL, Büchler MW, et al, editors. The pancreas. Vol. 1. Oxford: Blackwell; 1998. p. 163–8.

    Google Scholar 

  29. 29.

    Casper ES. Pancreatic cancer: How can we progress? [editorial]. Eur J Cancer. 1993;29A:171–2.

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Gapstur SM, Gann P. Is pancreatic cancer a preventable disease? [editorial]. JAMA. 2001;286:967–8.

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Zeiderman MR, Wyman A, Euinton HA, Simms JM, Rogers K. Diagnostic difficulties in patients with a pancreatic mass. BMJ. 1991;302:1395–6.

    PubMed  CAS  Google Scholar 

  32. 32.

    Cancer of the Pancreas Task Force. Staging of cancer of the pancreas. Cancer. 1981;47:1631–7.

    Article  Google Scholar 

  33. 33.

    Bakkevold KE, Arnesjo B, Kambestad B. Carcinoma of the pancreas and papilla of Vater: presenting symptoms, signs, and diagnosis related to stage and tumour site. A prospective multicentre trial in 472 patients. Norwegian Pancreatic Cancer Trial. Scand J Gastroenterol. 1992;27:317–25.

    PubMed  CAS  Google Scholar 

  34. 34.

    Maringhini A, Ciambra M, Raimondo M, et al. Clinical presentation and ultrasonography in the diagnosis of pancreatic cancer. Pancreas. 1993;8:146–50.

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Ridder GJ, Klempnauer J. Back pain in patients with ductal pancreatic cancer. Its impact on resectability and prognosis after resection. Scand J Gastroenterol. 1995;30:1216–20.

    PubMed  CAS  Google Scholar 

  36. 36.

    Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol. 1995;13:748–55.

    PubMed  CAS  Google Scholar 

  37. 37.

    Halder SL, McBeth J, Silman AJ, Thompson DG, Macfarlane GJ. Psychosocial risk factors for the onset of abdominal pain. Results from a large prospective population-based study. Int J Epidemiol. 2002;31:1219–25.

    PubMed  Article  Google Scholar 

  38. 38.

    Fernández E, Porta M, Malats N, Belloc J, Gallén M. Symptom to diagnosis interval and survival in cancers of the digestive tract. Dig Dis Sci. 2002;47:2434–40.

    PubMed  Article  Google Scholar 

  39. 39.

    Tishelman C, Taube A, Sachs L. Self-reported symptom distress in cancer patients: reflections of disease, illness or sickness? Soc Sci Med. 1991;33:1229–40.

    PubMed  Article  CAS  Google Scholar 

  40. 40.

    Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002;1:683–95.

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Wulfkuhle JD, Liotta LA, Petricoin EF. Early detection: Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3:267–75.

    PubMed  Article  CAS  Google Scholar 

  42. 42.

    Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol. 2004;15:24–30.

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Porta M, Fernández E, Alguacil J. Semiology, proteomics and the early detection of symptomatic cancer. J Clin Epidemiol. 2003;56:815–9.

    PubMed  Article  Google Scholar 

  44. 44.

    Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. 2004;96:353–6.

    PubMed  Article  Google Scholar 

  45. 45.

    Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004;4:309–14.

    PubMed  Article  CAS  Google Scholar 

  46. 46.

    Feinstein AR. Misguided efforts and future challenges for research on “diagnostic tests”. J Epidemiol Community Health. 2002;56:330–2.

    PubMed  Article  CAS  Google Scholar 

  47. 47.

    Rockhill B. Proteomic patterns in serum and identification of ovarian cancer. Lancet. 2002;360:169.

    PubMed  Article  Google Scholar 

  48. 48.

    Porta M, Malats N, Guarner L, et al. Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. J Epidemiol Community Health. 1999;53:702–9.

    PubMed  CAS  Article  Google Scholar 

  49. 49.

    Porta M, Jariod M, Malats N, et al. Prevalence of K-ras mutations at diagnosis and serum levels of DDT, DDE, PCBs and other organochlorine compounds in exocrine pancreatic cancer. In: Gress TM, editor. Molecular pathogenesis of pancreatic cancer. Amsterdam: IOS Press; 2000. p. 37–44.

    Google Scholar 

  50. 50.

    Porta M, Costafreda S, Malats N, et al. Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. Eur J Epidemiol. 2000;16:533–41.

    PubMed  Article  CAS  Google Scholar 

  51. 51.

    Soler M, Malats N, Porta M, et al. Medical conditions in patients with pancreatic and biliary diseases: validity and agreement between data from questionnaires and medical records. Dig Dis Sci. 1999;44:2469–77.

    PubMed  Article  CAS  Google Scholar 

  52. 52.

    Alguacil J, Porta M, Benavides FG, et al. Occupation and pancreatic cancer in Spain: a case-control study based on job titles. Int J Epidemiol. 2000;29:1004–13.

    PubMed  Article  CAS  Google Scholar 

  53. 53.

    Alguacil J, Kauppinen T, Porta M, et al. Risk of pancreatic cancer and occupational exposures in Spain. Ann Occupat Hyg. 2000;44:391–403.

    CAS  Google Scholar 

  54. 54.

    Malats N, Casals T, Porta M, Guarner L, Estivill X, Real FX. The cystic fibrosis transmembrane regulator (CFTR) DF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreas cancer. Gut. 2001;48:70–4.

    PubMed  Article  CAS  Google Scholar 

  55. 55.

    Real FX, Malats N, Lesca G, et al. Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreas cancer. Gut. 2002;50:653–7.

    PubMed  Article  CAS  Google Scholar 

  56. 56.

    Alguacil J, Porta M, Malats N, et al. Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. Carcinogenesis. 2002;23:101–6.

    PubMed  Article  CAS  Google Scholar 

  57. 57.

    Alguacil J, Porta M, Kauppinen T, Malats N, Kogevinas M, Carrato A. Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer. Int J Cancer. 2003;107:635–41.

    PubMed  Article  CAS  Google Scholar 

  58. 58.

    Gavaldà L, Porta M, Malats N, et al. Agreement between information supplied by the patient and a family member on medical history, consumption of tobacco, alcohol and coffee, and diet in cancer of the exocrine pancreas and extrahepatic biliary system. Gac Sanit. 1995;9:334–42.

    PubMed  Google Scholar 

  59. 59.

    International Classification of Diseases, Clinical Modification. 9th revision. Ann Arbor, MI: Commission on Professional and Hospital Activities; 1980.

  60. 60.

    International Union Against Cancer. TNM classification of malignant tumours. 4th ed., 2nd revision. Berlin: Springer; 1992.

    Google Scholar 

  61. 61.

    American Joint Committee on Cancer, TNM Committee of the International Union Against Cancer. Handbook for staging of cancer from the Manual for Staging of Cancer. 4th ed. Philadelphia: J.B. Lippincott; 1993.

    Google Scholar 

  62. 62.

    World Health Organization. International Classification of Diseases for Oncology (ICD-O-2). 2nd ed. Geneva: World Health Organization; 1990.

    Google Scholar 

  63. 63.

    Berg JW. Morphologic classification of human cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer Epidemiology and Prevention. 2nd ed. New York: Oxford University Press; 1996. p. 28–44.

    Google Scholar 

  64. 64.

    Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Oxford: Blackwell; 1987. p. 125–32, 205–9.

    Google Scholar 

  65. 65.

    Schlesselman JJ, Stolley PD. Case-control Studies. New York: Oxford University Press; 1982. p. 174–7.

    Google Scholar 

  66. 66.

    Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research. Belmont, CA: Lifetime Learning Publications; 1982. p. 343.

    Google Scholar 

  67. 67.

    Bland M. An Introduction to Medical Statistics. Oxford: Oxford Medical Publications; 1987. p. 241–65.

    Google Scholar 

  68. 68.

    Okusaka T, Okada S, Ueno H, et al. Abdominal pain in patients with resectable pancreatic cancer with reference to clinicopathologic findings. Pancreas. 2001;22:279–84.

    PubMed  Article  CAS  Google Scholar 

  69. 69.

    Passik SD, Breitbart WS. Depression in patients with pancreatic carcinoma: Diagnostic and treatment issues. Cancer. 1996;78:615–26.

    Google Scholar 

  70. 70.

    Porta M. Role of organochlorine compounds in the etiology of pancreatic cancer: A proposal to develop methodological standards. Epidemiology. 2001;12:272–6.

    PubMed  Article  CAS  Google Scholar 

  71. 71.

    Porta M, Zumeta E, Ruiz L, et al. Persistent toxic substances and public health in Spain. Int J Occupat Environ Health. 2003;9:112–7.

    Google Scholar 

  72. 72.

    Porta M, Kogevinas M, Zumeta E, et al. Concentraciones de compuestos tóxicos persistentes en la población española: el rompecabezas sin piezas y la protección de la salud pública. Gac Sanit. 2002;16:257–66.

    PubMed  CAS  Google Scholar 

  73. 73.

    Porta M, Malats N, Belloc J, Gallén M, Fernández E. Do we believe what patients say about their neoplastic symptoms? An analysis of factors that influence the interviewer’s judgement. Eur J Epidemiol. 1996;12:553–62.

    Article  Google Scholar 

  74. 74.

    Malats N, Belloc J, Gallén M, Porta M. Disagreement between hospital medical records and a structured patient interview on the type and date of the first symptom in cancers of the digestive tract. Rev Épidémiol Santé Publique. 1995;43:533–40.

    PubMed  CAS  Google Scholar 

  75. 75.

    Nebril BA, Filgueira LT, Calvo AP, et al. Importance of surgical staging in patients with cancer of the exocrine pancreas. Rev Esp Enferm Dig. 1993;83:447–52.

    Google Scholar 

  76. 76.

    Cubiella J, Castells A, Fondevila C, et al. Prognostic factors in nonresectable pancreatic adenocarcinoma: A rationale to design therapeutic trials. Am J Gastroenterol. 1999;94:1271–8.

    PubMed  Article  CAS  Google Scholar 

  77. 77.

    Sáenz A, Kuriansky J, Salvador L, et al. Thoracoscopic splanchnicectomy for pain control in patients with unresectable carcinoma of the pancreas. Surg Endosc. 2000;14:717–20.

    PubMed  Article  Google Scholar 

  78. 78.

    Mercadante S, Catala E, Arcuri E, et al. Celiac plexus block for pancreatic cancer pain: Factors influencing pain, symptoms and quality of life. J Pain Symptom Manage. 2003;26:1140–7.

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Consortia

Corresponding author

Correspondence to Miquel Porta.

Additional information

Members of the Multicentre Prospective Study on the Role of the Kras and other Genetic Alterations in the Diagnosis, Prognosis and Etiology of Pancreatic and Biliary Diseases (PANKRAS II) Study Group are mentioned in previous publications.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Porta, M., Fabregat, X., Malats, N. et al. Exocrine pancreatic cancer: Symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 7, 189–197 (2005). https://doi.org/10.1007/BF02712816

Download citation

Key words

  • pancreatic neoplasms/diagnosis
  • pancreatic neoplasms/epidemiology
  • signs and symptoms
  • diagnosis
  • cholestasis
  • jaundice
  • cachexia
  • pruritis
  • pain/diagnosis
  • presentation
  • stage
  • choluria
  • asthenia
  • anorexia
  • weight-loss
  • constitutional syndrome
  • epigastric mass
  • proteomics